41 I en pooled analyse af grupperne, der modtog 600/ 100 mg x 2, fra POWER - og DUET- forsøgene var tilstedeværelsen ved baseline af mindst 3 af mutationerne V11I, V32I, L33F, I47V, I50V, I54L eller M, T74P, L76V, I84V or L89V forbundet med et reduceret virologisk respons over for PREZISTA co- administreret med 100 mg ritonavir.
Baseline genotype or phenotype and virologic outcome In a pooled analysis of the 600/100 mg b.i.d. groups of the POWER and DUET trials, the presence at baseline of 3 or more of mutations V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V or L89V was associated with a decreased virologic response to PREZISTA co-administered with 100 mg ritonavir.